MedTech poised to outperform in 2027, Leerink says as Abbott upgraded
Leerink Partners upgraded Abbott Laboratories (ABT) to Outperform, predicting significant gains for the MedTech sector over the next 12-24 months. Analyst Mike Kratky cited a disconnect between MedTech's GDP contribution and S&P 500 weighting, approaching multi-year low valuations, and reset 2027 expectations as key factors. Abbott's positive risk-reward setup, attractive trading multiple, and constructive guidance were noted for its upgrade.
Global Point-of-Care Connectivity Solutions Market to Reach $1.7 Billion by 2032 | Abbott, Roche, Siemens Healthineers and GE HealthCare Accelerate AI-Driven Care
The global point-of-care connectivity solutions market is projected to grow from $1.1 billion in 2025 to $1.7 billion by 2032, driven by healthcare digitization and demand for real-time patient data. Key players like Abbott, Roche, Siemens Healthineers, and GE HealthCare are leveraging AI and other advanced technologies to enhance these solutions. The market is segmented by offering, application, end-use, and geography, with significant growth expected in the software segment and the China market.
This Abbott Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday
On Thursday, several top Wall Street analysts revised their ratings on a number of key companies. Notably, a Leerink Partners analyst upgraded Abbott Laboratories (NYSE:ABT) from Market Perform to Outperform, setting a new price target of $124. This report details the top five analyst upgrades, including actions on Reinsurance Group of America, Brown & Brown Inc, Fomento Economico Mexicano, and Marsh & McLennan Companies Inc, with corresponding new price targets.
Leerink Partners upgrades Abbott Laboratories to Outperform from Market Perform, sets price target at $124
Leerink Partners has upgraded Abbott Laboratories (ABT) to an Outperform rating from Market Perform, setting a new price target of $124. This target implies an 18.7% upside from the stock's closing price of $104.48 on November 18. This action follows other recent analyst ratings on Abbott Laboratories, with price targets ranging from $118 to $125.
Abbott Labs upgraded by Leerink Partners with a new price target
Leerink Partners has upgraded Abbott Labs (ABT) to Outperform from Market Perform, setting a new price target of $124.00. This analyst rating change was delivered by Quantisnow, highlighting the latest Wall Street sentiment towards the healthcare company. Historically, ABT's stock has shown varied reactions to previous headlines, with a median move of 1.1% after announcements.
Earnings Beat Might Change The Case For Investing In Stryker (SYK)
Stryker (SYK) reported strong third-quarter results with 10.3% adjusted EPS growth driven by margin gains and cost control, particularly from Endoscopy, Medical, and Mako orthopaedics. The company is focusing on robotics and strategic board appointments to support its defensive growth narrative. Despite ongoing operational and sentiment risks like debt and insider selling, the latest performance indicates that Stryker's strategy remains effective.
Morgan Stanley says this is the 'ultimate off-the-grid' stock as worries about tech outages increase
Morgan Stanley has an "overweight" rating on SpaceX, calling it the "ultimate off-the-grid" stock due to its independence from mainstream technology infrastructure. Amid increasing concerns about tech outages, the investment bank sees SpaceX's Starlink satellite internet service as a resilient option. The firm has set a $300 price target for SpaceX, representing a 109% upside from its recent closing price.
Here are Thursday's biggest analyst calls: Nvidia, Anthropic, SpaceX, Apple, Abbott Labs, Box, Strategy & more
Wolfe initiated Anthropic as outperform, citing it as "best-in-class" with significant growth potential. JPMorgan reiterated Apple as overweight due to strong consumer interest in the iPhone 18, particularly the Pro models. Bank of America initiated Viridian Therapeutics as a buy, noting its leadership in thyroid eye disease treatment.
Abbott Labs upgraded by Leerink Partners with a new price target
Leerink Partners has upgraded Abbott Labs (ABT) to Outperform from Market Perform, setting a new price target of $124.00. This analyst rating change highlights a more favorable outlook for the healthcare company. Historically, ABT's stock has shown mixed reactions to previous headlines, with a median move of 1.1% in either direction in the sessions following news.
KKR Finalizes Deal to Acquire Integer
KKR has completed its acquisition of Integer Holdings Corporation, a leading global medical device contract development and manufacturing organization (CDMO), in a transaction valued at approximately $5.7 billion. Integer stockholders received $127 per share in cash, and Integer's common stock has ceased trading on the New York Stock Exchange. This acquisition aims to accelerate Integer's growth strategy and further invest in its capabilities within the medical device industry.
ALGN: Align Technology Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
Align Technology Inc. has filed an SEC Form 8-K announcing the appointment of two new directors to its board: Paul Clancy, effective immediately, and Ian Bell, effective December 10, 2026. This expands the board to 13 members temporarily, before returning to 12 upon Raymond Larkin's retirement on December 31, 2026. The appointments add significant finance, strategy, and operations experience from the healthcare sector.
Douglas Roeder Bought 10% More Shares In Senseonics Holdings
Independent Non-Management Director Douglas Roeder recently purchased US$176k worth of Senseonics Holdings (NASDAQ:SENS) stock at US$10.32 per share, increasing his holding by 10%. This was the largest insider purchase in the last year, indicating optimism even at a higher price than the current US$10.16. Insiders collectively own about 8.4% of the company, suggesting alignment with shareholders, despite the company reporting a loss last year.
Insulin Delivery Devices Market to Reach US$ 43.11 Billion
The global insulin delivery devices market is projected to grow from US$ 22.04 billion in 2025 to US$ 43.11 billion by 2033, exhibiting an 8.8% CAGR, driven by the increasing prevalence of diabetes and technological advancements. North America leads the market with a 43.50% share, while Asia-Pacific is expected to experience the fastest growth. Key players like Medtronic, Insulet Corporation, and Tandem Diabetes Care are innovating with smart pens, automated insulin delivery systems, and wearable devices to improve diabetes management.
Electroceutical Devices Market Size, Share & Forecast 2036
The electroceutical devices market is projected to grow from USD 25.1 billion in 2026 to USD 49.2 billion by 2036, at a CAGR of 7.0%. This growth is driven by increasing adoption of advanced neuromodulation, expansion of closed-loop and personalized neuromodulation, and strategic portfolio consolidation among key players. Implantable devices, cardiovascular applications, and hospitals are expected to maintain their leading positions in the market segments.
What NRx Pharmaceuticals (NRXP) Said on Its Q3 Earnings Call
NRx Pharmaceuticals reported higher Q3 patient revenue and a narrower net loss, outlining plans to commercialize its recently FDA-approved preservative-free ketamine product and advance experimental treatments for depression. The company also detailed its cash position, pipeline developments including a subcutaneous ketamine formulation and a DARPA-funded trial, and its HOPE Therapeutics clinics. NRx aims for profitability by 2027 and is pursuing early-stage programs for ALS and schizophrenia through its GeNeuro division.
Abbott Laboratories stock underperforms Tuesday when compared to competitors
Abbott Laboratories (ABT) stock declined by 2.55% to $104.71 on Tuesday, underperforming the broader market as both the S&P 500 Index and Dow Jones Industrial Average also fell. This marks the second consecutive day of losses for the company's shares.
BridgeBio Reports New AHA and ISA 2026 Data Show Early and Broad Clinical Benefit of Acoramidis in ATTR-CM
BridgeBio Pharma announced new analyses from the Phase 3 ATTRibute-CM study and real-world evidence confirming the early and broad clinical benefits of acoramidis in treating transthyretin amyloid cardiomyopathy (ATTR-CM). Findings presented at the American Heart Association and International Symposium on Amyloidosis demonstrated that acoramidis significantly reduces heart failure events by 45% versus placebo, with benefits appearing within the first month. Real-world data also showed a 23% lower risk of worsening heart failure when acoramidis was used instead of tafamidis, reinforcing its potential as a first-line treatment option.
YARW
Yarrow Bioscience Inc. (YARW) is a clinical-stage biotechnology company listed on NASDAQ, focused on developing therapies for autoimmune thyroid diseases. The company is developing YB-101, a potential first-in-class antibody for Graves' disease and thyroid eye disease. Recent news includes SEC filings, analyst ratings from Jefferies and Guggenheim with Buy ratings, and a report on third-quarter 2026 financial results, which included approximately $172.5 million from an underwritten public offering and $268.9 million in cash and cash equivalents.
MiniMed and Tandem win FDA clearance for their first tubeless insulin pumps, setting up a 2027 fight with Insulet
MiniMed Group and Tandem Diabetes Care have both received FDA clearance for their first tubeless insulin pumps, setting the stage for a competitive market in 2027 against current leader Insulet. MiniMed Fit, with a seven-day wear time and 300-unit capacity, will launch in spring 2027, while Tandem's tubeless Mobi kit, offering a seven-day infusion set and 200-unit cartridge, is planned for the first half of 2027. Both companies aim to challenge Insulet's Omnipod, which currently dominates the tubeless pump market with a three-day wear time.
Is Abbott Laboratories (ABT) Undervalued On Medical Devices Growth And New Rapid Tests?
Abbott Laboratories (ABT) is gaining attention due to momentum in its Medical Devices unit, particularly with electrophysiology products and new rapid testing offerings. Despite a 12.62% year-to-date share price decline, analysts consider ABT undervalued with a fair value of $120.26, contingent on continued growth in medical technology and managing Nutrition legal risks. However, its P/E ratio of 40.2x is higher than industry averages, suggesting limited upside if market sentiment shifts.
MiniMed gets FDA nod for tubeless insulin pump
MiniMed has received FDA clearance for its first tubeless insulin pump, the MiniMed Fit, designed for individuals with Type 1 and Type 2 diabetes aged seven and older. The device can be worn for up to seven days, holds 300 units of insulin, and features a meal detection algorithm. MiniMed aims to compete with Insulet and Tandem Diabetes Care in the patch pump market, with a phased U.S. rollout planned for spring 2027.
FDA Clears MiniMed Fit™ -- World's First and Only Tubeless Insulin Pump with Up to Seven-Day Wear and Zero Interruptions
MiniMed (Nasdaq: MMED) has received FDA clearance for its MiniMed Fit, the company's first tubeless insulin pump, designed for individuals with Type 1 and Type 2 diabetes aged 7 and older. This innovative pump offers up to seven days of wear and a 300-unit insulin capacity, controllable via an app and featuring SmartGuard automated insulin delivery. A phased U.S. rollout is anticipated in spring 2027, following an early customer experience phase in fiscal Q4 2027, with access planned through pharmacies.
Abbott Laboratories price seeks a supportive bottom - Forecast today - 16-11-2026
Abbott Laboratories (ABT) recently edged higher, attempting to form a supportive base for a potential recovery. The stock has worked off overbought conditions on momentum indicators, which are now in oversold territory, increasing the likelihood of a near-term rebound. The outlook remains bullish as long as the $104.30 support level holds, with an expected target of $117.00.
Abbott extends change-in-control agreements, excludes CEO Robert B. Ford
Abbott has extended the terms of its change-in-control agreements for all named executive officers except for Chairman and CEO Robert B. Ford. Ford's agreement is set to expire at the end of 2026 and was not extended. The reason for this exclusion has not been disclosed.
Earnings Beat Could Be A Big Moment For Abbott Stock And Nutrition Split Plans
Abbott Laboratories recently reported strong third-quarter 2026 sales and earnings across key segments and announced plans to spin off its global Nutrition business into a separate public company by late 2027. The company's focus is now on how this spin-off and its medical devices pipeline will reshape its investment narrative, alongside ongoing efforts in diagnostics and margin expansion. Analysts are watching for execution on margins and the concentration of risk related to the Nutrition segment, while new product launches like the Panbio COVID-19/Flu A&B Self Test contribute to the diagnostics growth story.
Tandem’s Mobi pump wins FDA clearance for 7-day tubeless wearable set
Tandem Diabetes Care has received FDA clearance for a tubeless version of its miniaturized Mobi automated insulin delivery system, allowing it to be worn on the skin for up to seven days. This new cartridge and infusion set will be launched commercially in the first half of next year through pharmacy channels, providing an extended wear time compared to competitors. The Mobi pump, initially launched in 2024, was designed to be compatible with different wear options, meaning existing users will only need the new accessories.
Pfizer's 5.9% Yield vs. AbbVie's 53-Year Dividend Streak: Which Stock Is the Better Buy?
This article compares Pfizer (PFE) and AbbVie (ABBV) as investment options, particularly for income investors. Pfizer offers a high 5.9% dividend yield, making it attractive for maximizing cash flow, despite facing a patent cliff. AbbVie, a Dividend King with a 53-year dividend increase streak and a 2.5% yield, is presented as a better choice for investors seeking both income and growth, having successfully navigated its own patent cliff with strong new products.
Pfizer's 5.9% Yield vs. AbbVie's 53-Year Dividend Streak: Which Stock Is the Better Buy?
This article compares Pfizer (PFE) and AbbVie (ABBV) as investment options, particularly for income investors. Pfizer offers a high dividend yield of 5.9%, while AbbVie boasts a 53-year dividend increase streak and strong growth prospects after successfully navigating its own patent cliff. The choice between the two depends on whether an investor prioritizes maximizing current cash flow (Pfizer) or seeks a combination of income and growth with consistent dividend increases (AbbVie).
Digital Health in Chronic Disease: What's Working, What's Scaled, and What's Next
This article announces an HLTH Insider event sponsored by Vertex Pharmaceuticals, focusing on the current state and future of digital health in chronic disease management. The event aims to bring together executives from Pharma and Healthtech to discuss successful digital tools, the challenges of scaling them beyond point solutions, and how to foster effective partnerships to improve patient outcomes. The discussion will cover what's working, what's scaled, and what's next in this critical area of healthcare.
Should You Buy, Hold or Sell Abbott Stock Post-Q3 Earnings?
Abbott (ABT) delivered strong Q3 2026 results, with sales up 14.5% and adjusted EPS rising 9.2%, despite slightly missing consensus EPS estimates. The company plans to spin off its global Nutrition business by the end of 2027 to enhance strategic focus. While Abbott faces near-term headwinds in Electrophysiology and Diabetes Care, leading to a revised 2026 sales outlook, its diversified portfolio, new product launches in Cancer Diagnostics, and favorable valuation suggest a "Hold" recommendation.
Earnings call transcript: MDxHealth Q3 2026 revenue miss weighs on shares
MDxHealth reported Q3 2026 revenue of $22.7 million, significantly missing Wall Street's forecast of $28.75 million, which caused shares to decline. The company attributed the miss to accelerated sales-force turnover and a shift towards lower-margin liquid testing. Management expects Q3 to be the low point, with a gradual recovery anticipated to begin in 2027 as the sales team is rebuilt and new strategic initiatives, including AI, are implemented.
Tandem Diabetes Care Receives Multiple Health Canada Approvals for t:slim X2 Insulin Pump
Tandem Diabetes Care has received Health Canada approval for several significant updates to its t:slim X2 insulin pump with Control-IQ+ automated insulin delivery technology. These approvals include compatibility with Abbott’s FreeStyle Libre 3 Plus Sensor and expanded indications for use in individuals with type 1 diabetes during pregnancy and adults with type 2 diabetes. These advancements are expected to be available in Canada in the second quarter of 2027, broadening access to innovative diabetes management technology.
After $1M in year-earlier revenue, Freenome (FRNM) posts a profit on license revenue.
Freenome (FRNM) reported a significant increase in Q3 2026 revenue to $183.5 million, up from $1.0 million in the year-ago quarter, driven primarily by a $182.5 million license agreement with Exact Sciences following FDA approval of its SimpleScreen CRC test. This led to a net income of $60.1 million, a substantial improvement from a $64.5 million net loss previously. The company also launched SimpleScreen Lung, a laboratory-developed lung cancer screening test, and secured $295.5 million in net proceeds from a July business combination and PIPE financing.
Abbott vs. Medtronic: Which Dividend Stock Pays You More in 10 Years?
This article compares Abbott Laboratories (ABT) and Medtronic (MDT) as dividend stocks, analyzing their current yields, dividend growth rates, and financial health. While Medtronic currently has a higher yield, Abbott's faster dividend growth is projected to result in higher total payouts over a 10-year period. The analysis considers upcoming business spin-offs for both companies and their respective free cash flow trends.
Abbott Laboratories stock underperforms Thursday when compared to competitors
Abbott Laboratories (ABT) shares fell 1.87% to $107.25 on Thursday, marking its third consecutive day of losses. This decline occurred during a generally dismal trading session, with the S&P 500 Index (SPX) down 0.35% and the Dow Jones Industrial Average (DJIA) falling 0.36%. The stock's performance underperformed its competitors.
Abbott’s defibrillation lead lands FDA approval and CE mark
Abbott has received FDA approval and CE marking for its UltiSynq defibrillation lead, allowing its sale in the U.S. and European Union. This device is designed to deliver conduction system pacing and defibrillation therapy to treat patients at risk of sudden cardiac death caused by life-threatening tachyarrhythmias. Clinical data from the ASCEND CSP trial supported these authorizations, showing high implant success rates and effective defibrillation.
Abbott’s defibrillation lead lands FDA approval and CE mark
Abbott has received FDA approval and CE mark for its UltiSynq defibrillation lead, allowing it to be sold in the U.S. and Europe. This device is designed for left bundle branch area pacing and defibrillation therapy to treat patients at risk of sudden cardiac death from fast heart rhythms. Clinical data from the ASCEND CSP trial supported these authorizations, demonstrating high implant success rates and effective stimulation of the heart's natural conduction pathway.
Former Medtronic and Baxter International Executives Join Chapman & Co. Leadership Institute, Expanding Healthcare and MedTech Expertise
Chapman & Co. Leadership Institute has announced the addition of Jeanne Mason, former executive vice president and chief human resources officer of Baxter International, and Carla Skinner, former senior director of Medtronic's Global Sales Excellence, to its senior leadership team. This expansion aims to bolster the firm's expertise in healthcare, life sciences, and MedTech organizations, bringing decades of experience in leadership development, culture transformation, and organizational change. Their appointments are set to enhance the consultancy's ability to help clients align strong culture with robust business results in complex and highly regulated industries.
Infant Nutrition Market Report Examines Leading Companies And Growth Opportunities
The infant nutrition market is experiencing significant growth, projected to reach $64.3 billion by 2030, driven by rising birth rates, increased health awareness, and demand for specialized products. Key players like Abbott Laboratories and Nestlé SA are innovating with solutions like Sinergity, which mimics breast milk to improve infant health outcomes. The market is segmented by product type, meal type, and distribution channel, including various formulas and prepared baby foods.
What Are Abbott Stock Bears Missing?
Abbott Laboratories (ABT) plans to spin off its nutrition business, a move that analysts suggest bears might be overlooking. The company expects faster growth and higher profitability for its remaining medical devices, diagnostics, and medicines segments. While the nutrition unit has grown more slowly, its separation is projected to accelerate Abbott's overall sales growth and improve operating and gross margins, despite recent declines in reported margins.
ISRG Agrees to $450M Settlement: What Does It Mean for Investors?
Intuitive Surgical (ISRG) reported a significant impact on its third-quarter 2026 earnings due to a $450 million litigation settlement concerning its da Vinci ecosystem. While the settlement negatively affected GAAP net income, the company still showed strong underlying operating performance with revenues increasing 22% and procedures growing 15%. This agreement is also seen as a strategic move to strengthen customer relationships and ensure clarity regarding third-party servicing and remanufacturing of instruments.
Global X Aging Population ETF (AGNG.MX) stock price, news, quote and history
This page provides information on the Global X Aging Population ETF (AGNG.MX), including its stock price, news, and historical data. As of the close on November 5, the ETF traded at 772.00 MXN. A related article from Zacks suggests betting on healthcare ETFs due to the aging US population.
Did Profitable Quarter Just Shift AtriCure (ATRC) Stock Investment Narrative?
AtriCure (ATRC) reported a profitable third quarter in 2026, with revenue of US$154.45 million and net income of US$4.06 million, marking a significant shift from previous losses. The company also provided full-year 2026 guidance, indicating sustained profitability. This development suggests that AtriCure's cost structure and product mix are now effectively supporting earnings alongside growing sales, potentially altering the investment narrative for the medical equipment company.
Abbott Laboratories stock underperforms Wednesday when compared to competitors
Abbott Laboratories (ABT) stock experienced a decline of 1.06% to $109.29 on Wednesday, despite a generally positive trading day for the broader market. Both the S&P 500 Index and the Dow Jones Industrial Average saw gains, rising 1.31% and 0.49% respectively. This marks the second consecutive day of losses for Abbott Laboratories' stock.
Abbott’s UltiSynq defibrillation lead lands simultaneous US-EU approvals
Abbott's UltiSynq defibrillation lead has received simultaneous market approvals in the US and Europe, offering a new option for patients needing both conduction system pacing and defibrillation protection. The approvals were supported by the ASCEND CSP trial, which demonstrated a 97.5% major complication-free rate and high implantation success for the device, designed to treat irregular heart rhythms by directly targeting the heart's natural electrical pathways. This product expands Abbott’s cardiac rhythm management portfolio, providing a solution for patients indicated for implantable cardioverter defibrillator (ICD) or cardiac resynchronisation therapy defibrillator (CRT-D) therapy.
KPTIQ | Karyopharm Therapeutics Inc. Stock Overview (U.S.: OTC)
This article provides an overview of Karyopharm Therapeutics Inc. (KPTIQ) stock, including its current market status on the U.S. OTC market. It details analyst ratings, key financial metrics like revenue and net income, and information about major holders and key executives. The company is described as a commercial-stage pharmaceutical company focused on cancer and other diseases.
Spectral AI - Class A Share News - Latest Updates, Live News & More
Spectral AI's latest news indicates a challenging Q3 FY26 with sales missing estimates, despite EPS beating consensus. The company's revenue declined by 24.7% year-over-year, leading to a lowered full-year revenue guidance. However, Spectral AI secured significant non-dilutive funding and continues to showcase its DeepView System, which recently received FDA De Novo Classification and UKCA authorization, with commercial sales expected by the end of 2026.
Earnings call transcript: Freenome jumps on q3 2026 revenue surge and launch
Freenome reported a significant surge in Q3 2026 revenue, reaching $183.5 million, primarily due to a $180 million recognition from FDA approval of its SimpleScreen CRC test and its commercial launch. The company achieved profitability with diluted earnings of $0.58 per share, a substantial improvement from a loss in the prior year. Freenome's stock rose in after-hours trading, and the company outlined future milestones including additional cancer test readouts and plans for a multi-cancer detection launch.
Abbott’s UltiSynq Defibrillation Lead Gains U.S., EU Approvals
Abbott has received U.S. FDA and CE mark approvals for its UltiSynq defibrillation lead, which combines conduction system pacing (CSP) with defibrillation therapy using left bundle branch area pacing (LBBAP). This lead offers physicians another option for patients requiring both CSP and defibrillation protection. The approvals were supported by the ASCEND CSP IDE trial, which demonstrated the lead's safety and effectiveness with high implantation success and major complication-free rates.
Freenome Q3 2026 Earnings Call Transcript
Freenome (NASDAQ: FRNM) held its first earnings call as a public company, reporting a total revenue of $183.5 million for Q3 2026, primarily due to FDA approval and commercial launch of Simple Screen CRC. The company raised $310 million through its NASDAQ IPO and is focused on expanding its AI-enabled cancer screening platform and product pipeline, including new lung cancer tests and strategic partnerships with Abbott and Roche. Freenome anticipates future growth through continued innovation in test development, aiming for additional single and multi-cancer tests, while also working to broaden reimbursement coverage.